Cargando…
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
Drug resistance and tumor heterogeneity are formidable challenges in cancer medicine, which is particularly relevant for KRAS-mutant cancers, the epitome of malignant tumors recalcitrant to targeted therapy efforts and first-line chemotherapy. In this study, we delineate that KRAS-mutant lung cancer...
Autores principales: | Yang, Haitang, Liang, Shun-Qing, Xu, Duo, Yang, Zhang, Marti, Thomas M., Gao, Yanyun, Kocher, Gregor J., Zhao, Heng, Schmid, Ralph A., Peng, Ren-Wang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702198/ https://www.ncbi.nlm.nih.gov/pubmed/31431614 http://dx.doi.org/10.1038/s41389-019-0158-7 |
Ejemplares similares
-
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
por: Yang, Zhang, et al.
Publicado: (2021) -
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
por: Yang, Zhang, et al.
Publicado: (2022) -
Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma
por: Xu, Duo, et al.
Publicado: (2018) -
Synergistic activation of eIF4A by eIF4B and eIF4G
por: Nielsen, Klaus H., et al.
Publicado: (2011) -
MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer
por: Wang, Wanqin, et al.
Publicado: (2017)